retatrutide illegal ⚠️ Before you consider using retatrutide, know the facts. has not completed the FDA approval process, there is no official assessment confirming its safety or quality. The risks are real: 🚫 June 8, 2026: Reckless physicians

Clinical trials have demonstrated that patients can lose between 10% to 20% of their body weight, depending on the medication and adherence to treatment

These risks should always be discussed with your clinician before starting treatment

Noyce, A

26 The eGFR slope data in this analysis provide the clearest evidence yet that GLP-1 receptor agonists attenuate the rate of GFR decline, independent of SGLT2 inhibitor use, and suggest that GLP-1 receptor agonists should be used alongside SGLT2 inhibitors and other evidence-based kidney therapies to reduce loss of kidney function in people with type 2 diabetes

Having all documentation prepared in advance and readily available shortens this process from weeks to days

Zhang WL, Chi YL, Wang LZ, Liu H, Zhao LX, Su F